Shots:
- Forbius will receive up front and milestones while BMS will acquire Forbius’s TGF-beta program, including the lead investigational asset, AVID200. The transaction is expected to be closed in Q4’20
- Prior to closing, Forbius’ non-TGF-beta assets will be transferred to a newly formed private company, which will be retained by Forbius’ existing shareholders
- AVID200 is a highly potent and isoform-selective TGF-beta inhibitor that neutralizes TGF-beta 1 and -beta 3 with picomolar potency, currently being evaluated in P-I study for Oncology and Fibrosis
Click here to read full press release/ article | Ref: BMS | Image: Canvas
